• Company
• Xospata makes progress for reimb...up for DREC review
• by Eo, Yun-Ho Jun 23, 2023 05:45am

• Policy
• Scemblix is listed in July
• by Lee, Tak-Sun Jun 23, 2023 05:45am

• Company
• IND of LegoChem Bio's ADC was approved by the FDA
• by Hwang, Jin-joon Jun 23, 2023 05:44am

• Company
• Expansion of indications for Forxiga as a treatment for HFrE
• by Jung, Sae-Im Jun 23, 2023 05:43am

• Company
• GO for patent litigation, NO for suspension of execution
• by Kim, Jin-Gu Jun 22, 2023 04:14pm

• Policy
• Expansion of # of members of the Committee to around 105
• by Lee, Tak-Sun Jun 22, 2023 05:43am

• Company
• Leclaza confirms brain metastasis benefits
• by Hwang, byoung-woo Jun 22, 2023 05:41am

• Policy
• New drug pre-registration - post-evaluation non-face-to-face
• by Lee, Jeong-Hwan Jun 22, 2023 05:41am

• Policy
• MFDS cautious about strengthening regulations
• by Lee, Jeong-Hwan Jun 22, 2023 05:40am

• Policy
• Imported orphan drug specimen storage standards
• by Lee, Hye-Kyung Jun 22, 2023 05:40am